HC Wainwright Weighs in on Alumis’ Q2 Earnings (NASDAQ:ALMS)

Alumis Inc. (NASDAQ:ALMS) – Stock analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for Alumis in a research report issued on Friday, May 15th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($0.55) for the quarter, up from their prior estimate of ($0.60). HC Wainwright has a “Neutral” rating and a $25.00 price objective on the stock. The consensus estimate for Alumis’ current full-year earnings is ($3.06) per share. HC Wainwright also issued estimates for Alumis’ Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.72) EPS, FY2026 earnings at ($2.71) EPS, Q1 2027 earnings at ($0.72) EPS, Q2 2027 earnings at ($0.73) EPS, Q4 2027 earnings at ($0.64) EPS and FY2027 earnings at ($2.84) EPS.

A number of other brokerages have also recently weighed in on ALMS. Guggenheim raised their price target on Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Friday. Loop Capital set a $37.00 price target on Alumis in a research report on Wednesday, January 21st. Oppenheimer raised their price target on Alumis from $50.00 to $55.00 and gave the company an “outperform” rating in a research report on Monday, March 30th. Raymond James Financial initiated coverage on Alumis in a research report on Tuesday, March 10th. They issued a “strong-buy” rating and a $46.00 price target for the company. Finally, Stifel Nicolaus initiated coverage on Alumis in a research report on Wednesday, February 25th. They issued a “buy” rating and a $44.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Alumis has an average rating of “Moderate Buy” and an average price target of $40.10.

Alumis Stock Down 7.5%

Shares of ALMS stock opened at $21.15 on Tuesday. Alumis has a fifty-two week low of $2.76 and a fifty-two week high of $30.60. The stock has a market cap of $2.69 billion, a P/E ratio of -10.68 and a beta of -0.31. The business has a fifty day simple moving average of $24.31 and a 200-day simple moving average of $19.19.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. The firm had revenue of $1.74 million during the quarter, compared to analysts’ expectations of $2.10 million.

Institutional Trading of Alumis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. grew its holdings in Alumis by 320.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock valued at $26,000 after buying an additional 4,894 shares during the period. New York State Common Retirement Fund grew its holdings in Alumis by 173.7% in the 2nd quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock valued at $35,000 after buying an additional 7,467 shares during the period. CWM LLC grew its holdings in Alumis by 1,028.7% in the 3rd quarter. CWM LLC now owns 10,384 shares of the company’s stock valued at $41,000 after buying an additional 9,464 shares during the period. KBC Group NV purchased a new stake in Alumis in the 1st quarter valued at about $42,000. Finally, Strs Ohio grew its holdings in Alumis by 300.0% in the 1st quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $44,000 after buying an additional 1,500 shares during the period.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.